阿尔茨海默氏病的临床变体显示出具有神经病理的神经炎症特征的独特的神经炎症特征
Baayla D C Boon1,2,3,4,5, Irene Frigerio4,5, Danae de Gooijer2
1Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.
Neuropathology and applied neurobiology
|October 14, 2024
概括
神经炎症模式在阿尔茨海默氏病 (AD) 变体之间有所不同,影响临床表现. 了解这些独特的神经炎症特征是开发针对性AD疗法和生物标志物的关键.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 的临床异质性部分是由不同的神经病理学特征所解释的.
- 虽然tau和粉样β分布已知,但AD变体中神经炎症的神经解剖学传播仍然没有特征.
研究的目的:
- 在临床定义的AD变体中调查激活的髓质细胞,星体细胞和相补的与粉样β和酸化相对应的神经解剖分布.
主要方法:
- 从临床诊断的AD变体 (典型的AD,行为/失能AD,后皮层缩AD) 和对照对脑组织的死后神经病理评估.
- 使用数字病理学进行酸化,粉样β,CD68,MHC-II,C4b和GFAP分布的定量分析.
主要成果:
- 在每个AD变体中观察到化陶和神经炎症的独特神经解剖学模式.
- 粉样蛋白-β是新皮层主导的,在行为性/失执行性AD中具有特定的区域性增加.
- 神经炎症标志物 (CD68,MHC-II,C4b,GFAP) 显示了变异特异分布,与AD神经病理明显相关.
结论:
- 神经炎症在阿尔茨海默氏症的发病过程中起到变异特异性的作用,有助于临床异质性.
- 这些发现对开发针对性,基于神经炎症的生物标志物和AD治疗方法有影响.
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97


